[Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study].
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang S.H. | - |
dc.contributor.author | Jeen Y.T. | - |
dc.contributor.author | Koo J.S. | - |
dc.contributor.author | Koo Y.S. | - |
dc.contributor.author | Kim K.O. | - |
dc.contributor.author | Kim Y.S. | - |
dc.contributor.author | Kim S.Y. | - |
dc.contributor.author | Moon J.S. | - |
dc.contributor.author | Park J.J. | - |
dc.contributor.author | Baek I.H. | - |
dc.contributor.author | Park S.C. | - |
dc.contributor.author | Lee S.J. | - |
dc.contributor.author | Lee J.H. | - |
dc.contributor.author | Choung R.S. | - |
dc.contributor.author | Choi S.C. | - |
dc.date.available | 2020-11-02T22:42:45Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.issn | 2233-6869 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/11266 | - |
dc.description.abstract | Antispasmodic agents have been used in the management of irritable bowel syndrome. However, systematic reviews have come to different conclusions about the efficacy in irritable bowel syndrome. Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium. We compared fenoverine with trimebutine for the treatment of patients with IBS. A multicenter, randomized, double-blind, non-inferiority clinical study was conducted to compared fenoverine with trimebutine. Subjects were randomized to receive either fenoverine (100 mg three times a day) or trimebutine (150 mg three times a day) for 8 weeks. A total of 197 patients were analyzed by the intention-to-treat approach. The primary endpoint was the proportion of patients who had 30% reduction in abdominal pain or discomfort measured by bowel symptom scale (BSS) score at week 8 compared to the baseline. The secondary endpoints were changes of abdominal bloating, diarrhea, constipation, overall and total scores of BSS, and overall satisfaction. At week 8, fenoverine was shown to be non-inferior to trimebutine (treatment difference, 1.76%; 90% CI, -10.30-13.82; p=0.81); 69.23% (54 of 78 patients) of patients taking fenoverine and 67.47% (56 of 83 patients) of patients taking trimebutine showed 30% reduction in abdominal pain or discomfort compared to the baseline. There results of the secondary endpoints were also comparable between the fenoverine group and the trimebutine group. Fenoverine is non-inferior to trimebutine for treating IBS in terms of both efficacy and tolerability. | - |
dc.format.extent | 10 | - |
dc.language | 한국어 | - |
dc.language.iso | KOR | - |
dc.title | [Efficacy of fenoverine and trimebutine in the management of irritable bowel syndrome: multicenter randomized double-blind non-inferiority clinical study]. | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4166/kjg.2013.62.5.278 | - |
dc.identifier.scopusid | 2-s2.0-84903000431 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.62, no.5, pp 278 - 287 | - |
dc.citation.title | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.volume | 62 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 278 | - |
dc.citation.endPage | 287 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001819895 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | cholinergic receptor blocking agent | - |
dc.subject.keywordPlus | fenoverine | - |
dc.subject.keywordPlus | phenothiazine derivative | - |
dc.subject.keywordPlus | trimebutine | - |
dc.subject.keywordPlus | abdominal pain | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | constipation | - |
dc.subject.keywordPlus | controlled clinical trial | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | diarrhea | - |
dc.subject.keywordPlus | double blind procedure | - |
dc.subject.keywordPlus | drug administration | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | irritable colon | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | severity of illness index | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | Abdominal Pain | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Constipation | - |
dc.subject.keywordPlus | Diarrhea | - |
dc.subject.keywordPlus | Double-Blind Method | - |
dc.subject.keywordPlus | Drug Administration Schedule | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Irritable Bowel Syndrome | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Parasympatholytics | - |
dc.subject.keywordPlus | Phenothiazines | - |
dc.subject.keywordPlus | Severity of Illness Index | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.subject.keywordPlus | Trimebutine | - |
dc.subject.keywordAuthor | Fenoverine | - |
dc.subject.keywordAuthor | Trimebutine | - |
dc.subject.keywordAuthor | Irritable bowel syndrome | - |
dc.subject.keywordAuthor | Clinical study | - |
dc.subject.keywordAuthor | 페노베린 | - |
dc.subject.keywordAuthor | 트리메뷰틴 | - |
dc.subject.keywordAuthor | 과민성 장 증후군 | - |
dc.subject.keywordAuthor | 임상시험 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.